IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Ryoichi NAGATA : **Attn: BOX PCT**

Serial No. [NEW] : **Docket No. 2001-1906A**

Filed December 28, 2001 :

PREPARATION FOR NASAL ABSORPTION OF INSULIN :
[Corresponding to PCT/JP01/03642 Filed April 26, 2001]

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

In the interest of reducing PTO filing fees, please amend the present application as follows:

IN THE CLAIMS:

Please amend claims 3-8 and 10 as follows:

3. **(Amended)** The formulation according to Claim 1, in which the porous, spherical calcium carbonate has a particle diameter in the substantial range of 18-115 μm.

4. **(Amended)** The formulation according to Claim 1, in which the porous, spherical calcium carbonate has a particle diameter in the substantial range of 20-32 μm.

5. **(Amended)** The formulation according to Claim 1, in which the porous, spherical calcium carbonate has a particle diameter in the substantial range of 20-32 μm, and a median particle diameter of 22 μm or greater and less than 30 μm

ATTACHMENT E

6. **(Amended)** The formulation according to Claim 1, in which the porous, spherical calcium carbonate has a particle diameter in the range of 20-32 μm.

7. **(Amended)** The formulation according to Claim 1, in which the insulin content of the component composed of insulin and porous, spherical calcium carbonate is 0.1-50% by weight based on the total weight of the component.

8. **(Amended)** The formulation according to Claim 1, in which the porous, spherical calcium carbonate has a relative surface area of 1.5 m^2/g or greater.

10. **(Amended)** The formulation according to Claim 1, in which the insulin content of the component composed of insulin and calcium carbonate is 0.1-50% by weight based on the total weight of the component.

REMARKS

The above amendment is presented to eliminate multiple dependent claims, thereby reducing PTO filing fees.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is entitled "**Version with Markings to Show Changes Made**".

Favorable action on the merits is now requested.

Respectfully submitted,

Ryoichi NAGATA

By _____
Matthew Jacob
Registration No. 25,154
Attorney for Applicant

MJ/pjm
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
December 28, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 3-8 and 10 have been amended as follows:

3. **(Amended)** The formulation according to Claim 1 [or 2], in which the porous, spherical calcium carbonate has a particle diameter in the substantial range of 18-115 μm.

4. **(Amended)** The formulation according to Claim 1 [or 2], in which the porous, spherical calcium carbonate has a particle diameter in the substantial range of 20-32 μm.

5. **(Amended)** The formulation according to Claim 1 [or 2], in which the porous, spherical calcium carbonate has a particle diameter in the substantial range of 20-32 μm, and a median particle diameter of 22 μm or greater and less than 30 μm.

6. **(Amended)** The formulation according to Claim 1 [or 2], in which the porous, spherical calcium carbonate has a particle diameter in the range of 20-32 μm.

7. **(Amended)** The formulation according to [any of Claims 1-6] Claim 1, in which the insulin content of the component composed of insulin and porous, spherical calcium carbonate is 0.1-50% by weight based on the total weight of the component.

8. **(Amended)** The formulation according to [any of Claims 1-7] Claim 1, in which the porous, spherical calcium carbonate has a relative surface area of 1.5 m^2/g or greater.

10. **(Amended)** The formulation according to [any of Claims 1-9] Claim 1, in which the insulin content of the component composed of insulin and calcium carbonate is 0.1-50% by weight based on the total weight of the component.